<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-56464" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Argatroban</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mahat</surname>
            <given-names>Krishna C.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sedhai</surname>
            <given-names>Yub Raj</given-names>
          </name>
          <aff>Virginia Commonwealth Un School of Med</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Krishnan</surname>
            <given-names>Prathik</given-names>
          </name>
          <aff>SUNY Upstate Medical University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Krishna Mahat declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Yub Raj Sedhai declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Prathik Krishnan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-56464.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Argatroban is a medication used to manage heparin-induced thrombocytopenia (HIT), which is a rare, life-threatening complication of heparin therapy. It is a direct thrombin inhibitor, a class of anticoagulant drugs. This activity outlines the indications, action, and contraindications for argatroban as a valuable agent in the prophylaxis and treating thrombosis in patients with HIT. This activity also highlights the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the healthcare team in the management of patients with heparin-induced thrombocytopenia.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of argatroban.</p></list-item><list-item><p>Describe the potential adverse effects of argatroban.</p></list-item><list-item><p>Review the appropriate monitoring for patients on argatroban.</p></list-item><list-item><p>Discuss interprofessional team strategies for improving care coordination and communication to advance argatroban and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=56464&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=56464">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-56464.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Argatroban is a direct thrombin inhibitor (DTI)&#x000a0;first introduced&#x000a0;in Japan in 1990 for the treatment of peripheral vascular diseases.<xref ref-type="bibr" rid="article-56464.r1">[1]</xref> It has approval from the US FDA&#x000a0;for the following indications:</p>
        <list list-type="order">
          <list-item>
            <p>In 2000 it received approval for prophylaxis and treatment of thrombosis in patients with HIT (heparin-induced thrombocytopenia) and HITTS (heparin-induced thrombocytopenia and thrombosis syndrome). Two large prospective, historical controlled studies ARG-911 and ARG-915, have demonstrated the efficacy of argatroban in patients with HIT. Argatroban produces an effective and predictable anticoagulant effect, is non-immune, and increases the platelet count.<xref ref-type="bibr" rid="article-56464.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>In 2002 as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI) who have HIT or are at risk of it.<xref ref-type="bibr" rid="article-56464.r3">[3]</xref>&#x000a0;The efficacy and safety of argatroban in patients undergoing PCI have been established in three prospective studies the ARG-216, ARG-310, and ARG-311.</p>
          </list-item>
        </list>
        <p>Heparin-induced thrombocytopenia is an uncommon but potentially life-threatening condition&#x000a0;that occurs during or following recent heparin therapy (unfractionated heparin (UFH) and low molecular weight heparin), characterized by a drop in platelet count and paradoxical prothrombotic state. In patients under UFH therapy for more than five days, the incidence of HIT has been found up to 3%.<xref ref-type="bibr" rid="article-56464.r4">[4]</xref>&#x000a0;The formation of IgG antibodies to platelet factor 4/heparin complex leads to immune-mediated destruction and simultaneous activation of platelets leading to a hypercoagulable state and venous and arterial thrombosis, most common being deep vein thrombosis (DVT), pulmonary embolism, and skin necrosis. Thus, it is imperative to stop all forms of heparin and promptly start an alternative anticoagulant that does not cross-react with the circulating antibodies. Direct thrombin inhibitors argatroban, lepirudin, and bivalirudin are first-line agents used as an anticoagulant in the treatment of HIT. Other anticoagulants that can be options are danaparoid (discontinued in the USA) and fondaparinux. These agents act via antithrombin dependent mechanism.<xref ref-type="bibr" rid="article-56464.r5">[5]</xref></p>
        <p>
<bold>Non-FDA Uses</bold>
</p>
        <p>1. As an anticoagulant during cardiopulmonary bypass in HIT.</p>
        <p>2. As an anticoagulant during renal replacement therapy with or without HIT<xref ref-type="bibr" rid="article-56464.r6">[6]</xref></p>
        <p>3. As an alternative anticoagulant in cases of heparin resistance, especially in critically ill patients<xref ref-type="bibr" rid="article-56464.r7">[7]</xref></p>
        <p>4. Argatroban has approval in Japan for&#x000a0;</p>
        <p>&#x000a0; &#x000a0;a. Improvement of neurological symptoms in acute cerebral thrombosis within 48 hours of onset (excluding lacunar type).</p>
        <p>&#x000a0; &#x000a0;b. Improvement of ulcers and rest pain in chronic arterial occlusion.</p>
        <p>&#x000a0; &#x000a0;c. Anticoagulation in the extracorporeal circuit (during dialysis) in patients with congenital antithrombin deficiency or decreased antithrombin concentrations.<xref ref-type="bibr" rid="article-56464.r8">[8]</xref></p>
      </sec>
      <sec id="article-56464.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Argatroban is a synthetic compound based on the structure of L- arginine. It is a direct thrombin inhibitor that binds reversibly to the active site of thrombin and inhibits its downstream action. In contrast, indirect thrombin inhibitors like heparin exert their anticoagulant effect via activation of antithrombin.<xref ref-type="bibr" rid="article-56464.r6">[6]</xref></p>
        <p>Thrombin (clotting factor IIa) is a serine protease that has a central role in coagulation. It is the final enzyme in the coagulation cascade that, upon activation from prothrombin, converts fibrinogen to fibrin, activates procoagulant factors V, VIII, XI, and XIII, and activates platelets.</p>
        <p>Univalent DTIs like argatroban and melagatran bind only at the active site of thrombin, whereas bivalent DTIs like hirudin and bivalirudin bind to two sites of thrombin: the active site and exosite I, a positively charged region in the thrombin molecule, which is also a recognition site for many physiologic substrates like fibrinogen, protein C, factor V and thrombomodulin (thrombin receptor in endothelial cells).<xref ref-type="bibr" rid="article-56464.r9">[9]</xref></p>
        <p>Unlike heparin, which acts only on soluble thrombin, argatroban acts on both soluble and clot-bound thrombin because of its low molecular weight. It shows linear pharmacokinetic properties after starting an intravenous infusion. The drug concentration and anticoagulant effects attain steady-state levels 1 to 3 hours after the start of infusion. Since it acts on the final step of coagulation, most of the parameters of coagulation, eg, activated partial thromboplastin time (aPTT), activated clotting time (ACT), prothrombin time (PT), the international normalized ratio(INR), and thrombin time (TT) are prolonged rapidly and in a dose-dependent manner. The elimination half-life of argatroban is 39 to 51 minutes. This short half-life is desirable, given the risk of potential bleeding and the lack of a specific antidote. Anticoagulant effects gradually&#x000a0;decline and reach the pretreatment level within 2 to 4 hours after stopping the infusion. However, in patients with impaired hepatic function, it may take 6 to 20 hours&#x000a0;for its effects to wear off.<xref ref-type="bibr" rid="article-56464.r6">[6]</xref></p>
        <p>Argatroban is metabolized primarily by hydroxylation and aromatization via cytochrome P450 enzymes and excreted mainly via feces. However, significant drug interactions have not occurred with CYP3A4/5 inhibitors like erythromycin, digoxin, and acetaminophen.<xref ref-type="bibr" rid="article-56464.r10">[10]</xref></p>
        <p>Often in patients with HIT, long-term anticoagulation with oral warfarin is needed. When transitioning from argatroban to warfarin, INR may be elevated due to the additive effects of both drugs. In the absence of clear guidelines, the supratherapeutic level of INR&#x0003e;5 during such transition and overlap has no association with an increased risk of bleeding.<xref ref-type="bibr" rid="article-56464.r11">[11]</xref> Warfarin therapy should not start unless the platelet count has recovered above 150,000/mm<sup>3</sup>&#x000a0;and the patient is on therapeutic anticoagulation with non-heparin anticoagulants like argatroban. As a general rule, warfarin and argatroban should overlap for at least five days before discontinuing argatroban and continuing with warfarin monotherapy.</p>
      </sec>
      <sec id="article-56464.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Argatroban is available as an intravenous solution of 1 mg/ml.</p>
        <p><bold>Heparin-induced thrombocytopenia</bold>: Discontinue heparin and obtain baseline aPTT. For adult patients, the recommended dose is 2 mcg/kg/min, administered as a continuous intravenous infusion. Lower doses are used in critically ill patients, e.g., patients with multiorgan failure or severe anasarca.&#x000a0;In a study by Beiderlinden M., et al. performed on 24 critically ill patients with multiorgan dysfunction syndrome (MODS) and HIT, argatroban infusion of 2 mcg/kg/min for 4 hours resulted in excessive anticoagulation and even resulted in bleeding complications in&#x000a0;three patients but with infusion at starting dose of 0.2 mcg/kg/min, sufficient anticoagulation was achieved with no bleeding complications.<xref ref-type="bibr" rid="article-56464.r12">[12]</xref></p>
        <p>Monitoring: Monitor aPTT (target range of 1.5 to 3 times of initial baseline, not to exceed 100 seconds).&#x000a0;</p>
        <p>Dosage adjustment: Adjust the dose (not to exceed 10 mcg/kg/min) to maintain aPTT in the target range.</p>
        <p><bold>Percutaneous coronary intervention: </bold>Administer a bolus of 350 mcg/kg over 3 to 5 minutes and start an infusion at the rate of 25 mcg/kg/min.</p>
        <p>Check an activated clotting time (ACT) 5 to 10 minutes after completing the bolus dose.</p>
        <p>If the ACT &#x0003e; 300 seconds: Proceed with the PCI.</p>
        <p>If the ACT &#x0003c; 300 seconds: Administer an additional intravenous bolus dose of 150 mcg/kg, increase the infusion dose to 30 mcg/kg/min, and check the ACT 5 to 10 minutes later.</p>
        <p>If the ACT&#x0003e; 450 seconds: Decrease the infusion rate to 15 mcg/kg/min and check the ACT 5 to 10 minutes later.</p>
        <p>Titration of the dose should continue until ACT is in the therapeutic range (between 300 and 450 seconds).<xref ref-type="bibr" rid="article-56464.r6">[6]</xref></p>
        <p>Argatroban use requires caution in patients with hepatic dysfunction, especially in patients with total serum bilirubin &#x0003e;1.5 mg/dl. In such patients, a lower dose should be used (starting infusion rate from 0.5 mcg/kg/min).<xref ref-type="bibr" rid="article-56464.r6">[6]</xref><xref ref-type="bibr" rid="article-56464.r13">[13]</xref>&#x000a0;However, no dosage adjustment is necessary for patients with renal dysfunction.<xref ref-type="bibr" rid="article-56464.r10">[10]</xref><xref ref-type="bibr" rid="article-56464.r3">[3]</xref></p>
      </sec>
      <sec id="article-56464.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most common adverse effect of argatroban, as with other anticoagulants, is bleeding, which can manifest as gastrointestinal, genitourinary, intracranial, retroperitoneal bleeding, hemoptysis, and other minor bleedings.<xref ref-type="bibr" rid="article-56464.r14">[14]</xref> Non-hemorrhagic complications include hypotension, dyspnea, fever, sepsis, and cardiac arrest. When used in PCI, chest pain, back pain, nausea, vomiting, hypotension, and headache can occur.<xref ref-type="bibr" rid="article-56464.r10">[10]</xref></p>
      </sec>
      <sec id="article-56464.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Argatroban, like other anticoagulants, is contraindicated in overt bleeding.<xref ref-type="bibr" rid="article-56464.r6">[6]</xref></p>
        <p>When argatroban is used in patients with increased bleeding risk like severe hypertension, after major surgery, immediately following lumbar puncture, spinal anesthesia, particular caution, and vigilance are necessary.</p>
        <p>Avoid argatroban in patients with a history of hypersensitivity to it or any of its components in the dosage form.</p>
      </sec>
      <sec id="article-56464.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>In patients with HIT, aPTT is commonly useful for monitoring argatroban therapy. Clinicians should obtain a baseline aPTT, and the initial dosing should be adjusted to obtain a steady-state aPTT of 1.5 to 3 times baseline (not to exceed 100 seconds). The aPTT should also be obtained 2 hours after the initiation of therapy and after any change in dosage.<xref ref-type="bibr" rid="article-56464.r6">[6]</xref><xref ref-type="bibr" rid="article-56464.r15">[15]</xref></p>
        <p>In the PCI setting, where a higher argatroban dose is used, activated clotting time (ACT) is used to monitor therapy.</p>
      </sec>
      <sec id="article-56464.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The toxicity of argatroban from supratherapeutic dosage is related to its anticoagulant effect. There is no antidote to reverse its actions.<xref ref-type="bibr" rid="article-56464.r16">[16]</xref> In case of overdose, stop the drug and initiate appropriate transfusion therapy, eg, fresh frozen plasma.<xref ref-type="bibr" rid="article-56464.r17">[17]</xref>&#x000a0;Patients with hepatic dysfunction are particularly susceptible to the excessive anticoagulant effect of argatroban due to reduced clearance. In such patients, the reversal of its effect takes a longer time.</p>
      </sec>
      <sec id="article-56464.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Heparin products see frequent use in hospitals, including line flushes, catheters, to DVT prophylaxis in patients with prolonged hospitalization. It is reasonable to obtain platelet counts after heparin therapy. Any fall in platelet count requires evaluation, and a 4T score (degree of thrombocytopenia, timing relative to heparin exposure, presence of thrombosis, and other causes for thrombocytopenia) should be calculated if HIT is suspected. Clinicians, pharmacists, and nurses should be aware of HIT pathology. Argatroban is indicated only in Type II HIT, not in Type I. Type I HIT can be differentiated from Type II by a milder drop in platelet count, earlier onset of thrombocytopenia, and absence of antibodies. Since argatroban is expensive and can have potential bleeding complications, it is necessary to ensure its use is in the correct clinical scenario. Patients on argatroban therapy should have frequent monitoring of aPTT or ACT, and any signs suggestive of bleeding or fall in hemoglobin should be promptly reported to the healthcare team so that the clinician can promptly discontinue argatroban and initiate transfusion therapy.</p>
      </sec>
      <sec id="article-56464.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=56464&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=56464">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/56464/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=56464">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-56464.s11">
        <title>References</title>
        <ref id="article-56464.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kikelj</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Peptidomimetic thrombin inhibitors.</article-title>
            <source>Pathophysiol Haemost Thromb</source>
            <season>2003 Sep-2004 Dec</season>
            <volume>33</volume>
            <issue>5-6</issue>
            <fpage>487</fpage>
            <page-range>487-91</page-range>
            <pub-id pub-id-type="pmid">15692265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-56464.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jeske</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Walenga</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Fareed</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Pharmacology of argatroban.</article-title>
            <source>Expert Opin Investig Drugs</source>
            <year>1999</year>
            <month>May</month>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>625</fpage>
            <page-range>625-54</page-range>
            <pub-id pub-id-type="pmid">15992120</pub-id>
          </element-citation>
        </ref>
        <ref id="article-56464.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hassan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Awaisu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Al-Meman</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Aziz</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>The Pharmacotherapy of Heparin-Induced Thrombocytopenia (HIT) : A Review of Contemporary Therapeutic Challenges in Clinical Practice.</article-title>
            <source>Malays J Med Sci</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>3</fpage>
            <page-range>3-13</page-range>
            <pub-id pub-id-type="pmid">22589618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-56464.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moledina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chakir</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gandhi</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>A synopsis of the clinical uses of argatroban.</article-title>
            <source>J Thromb Thrombolysis</source>
            <year>2001</year>
            <month>Oct</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>141</fpage>
            <page-range>141-9</page-range>
            <pub-id pub-id-type="pmid">11729365</pub-id>
          </element-citation>
        </ref>
        <ref id="article-56464.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arepally</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Ortel</surname>
                <given-names>TL</given-names>
              </name>
            </person-group>
            <article-title>Heparin-induced thrombocytopenia.</article-title>
            <source>Annu Rev Med</source>
            <year>2010</year>
            <volume>61</volume>
            <fpage>77</fpage>
            <page-range>77-90</page-range>
            <pub-id pub-id-type="pmid">20059332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-56464.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grouzi</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Update on argatroban for the prophylaxis and treatment of heparin-induced thrombocytopenia type II.</article-title>
            <source>J Blood Med</source>
            <year>2014</year>
            <volume>5</volume>
            <fpage>131</fpage>
            <page-range>131-41</page-range>
            <pub-id pub-id-type="pmid">25152637</pub-id>
          </element-citation>
        </ref>
        <ref id="article-56464.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Treichl</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bachler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lorenz</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Friesenecker</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Oswald</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schlimp</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Pedross</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fries</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of argatroban in critically ill patients with heparin resistance: a retrospective analysis.</article-title>
            <source>Semin Thromb Hemost</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>61</fpage>
            <page-range>61-7</page-range>
            <pub-id pub-id-type="pmid">25594496</pub-id>
          </element-citation>
        </ref>
        <ref id="article-56464.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ikoma</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Development of argatroban as an anticoagulant and antithrombin agent in Japan.</article-title>
            <source>Pathophysiol Haemost Thromb</source>
            <year>2002</year>
            <volume>32 Suppl 3</volume>
            <fpage>23</fpage>
            <page-range>23-8</page-range>
            <pub-id pub-id-type="pmid">12811008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-56464.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yeh</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Stafford</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Fredenburgh</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Weitz</surname>
                <given-names>JI</given-names>
              </name>
            </person-group>
            <article-title>Dabigatran and Argatroban Diametrically Modulate Thrombin Exosite Function.</article-title>
            <source>PLoS One</source>
            <year>2016</year>
            <volume>11</volume>
            <issue>6</issue>
            <fpage>e0157471</fpage>
            <pub-id pub-id-type="pmid">27305147</pub-id>
          </element-citation>
        </ref>
        <ref id="article-56464.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bambrah</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Pham</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Rana</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Argatroban in heparin-induced thrombocytopenia: rationale for use and place in therapy.</article-title>
            <source>Ther Adv Chronic Dis</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>302</fpage>
            <page-range>302-4</page-range>
            <pub-id pub-id-type="pmid">24179672</pub-id>
          </element-citation>
        </ref>
        <ref id="article-56464.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hursting</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Macfarlane</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia.</article-title>
            <source>Clin Appl Thromb Hemost</source>
            <year>2005</year>
            <month>Jul</month>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>279</fpage>
            <page-range>279-87</page-range>
            <pub-id pub-id-type="pmid">16015413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-56464.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beiderlinden</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Treschan</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>G&#x000f6;rlinger</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Argatroban anticoagulation in critically ill patients.</article-title>
            <source>Ann Pharmacother</source>
            <year>2007</year>
            <month>May</month>
            <volume>41</volume>
            <issue>5</issue>
            <fpage>749</fpage>
            <page-range>749-54</page-range>
            <pub-id pub-id-type="pmid">17440009</pub-id>
          </element-citation>
        </ref>
        <ref id="article-56464.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levine</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Hursting</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>McCollum</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction.</article-title>
            <source>Chest</source>
            <year>2006</year>
            <month>May</month>
            <volume>129</volume>
            <issue>5</issue>
            <fpage>1167</fpage>
            <page-range>1167-75</page-range>
            <pub-id pub-id-type="pmid">16685006</pub-id>
          </element-citation>
        </ref>
        <ref id="article-56464.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klingele</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Enkel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Speer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bomberg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Baerens</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sch&#x000e4;fers</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Bleeding complications after cardiac surgery, before anticoagulation start and then with argatroban or heparin in the early postoperative setting.</article-title>
            <source>J Cardiothorac Surg</source>
            <year>2020</year>
            <month>Jan</month>
            <day>28</day>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>27</fpage>
            <pub-id pub-id-type="pmid">31992340</pub-id>
          </element-citation>
        </ref>
        <ref id="article-56464.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koster</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Harder</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mertzlufft</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>The direct thrombin inhibitor argatroban: a review of its use in patients with and without HIT.</article-title>
            <source>Biologics</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>1</volume>
            <issue>2</issue>
            <fpage>105</fpage>
            <page-range>105-12</page-range>
            <pub-id pub-id-type="pmid">19707320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-56464.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Knoblauch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pollak</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Toxicity of argatroban overdose in a 65-year-old man.</article-title>
            <source>Am J Hematol</source>
            <year>2005</year>
            <month>Jul</month>
            <volume>79</volume>
            <issue>3</issue>
            <fpage>248</fpage>
            <page-range>248-9</page-range>
            <pub-id pub-id-type="pmid">15981224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-56464.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yee</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Kuter</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Successful recovery after an overdose of argatroban.</article-title>
            <source>Ann Pharmacother</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>40</volume>
            <issue>2</issue>
            <fpage>336</fpage>
            <page-range>336-9</page-range>
            <pub-id pub-id-type="pmid">16449547</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
